as of 07-22-2026 1:31pm EST
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 57.9M | IPO Year: | 2020 |
| Target Price: | $5.38 | AVG Volume (30 days): | 557.6K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.33 | EPS Growth: | 7.64 |
| 52 Week Low/High: | $1.13 - $3.86 | Next Earning Date: | 04-29-2026 |
| Revenue: | $90,497,000 | Revenue Growth: | 8.01% |
| Revenue Growth (this year): | 2.48% | Revenue Growth (next year): | 18.46% |
| P/E Ratio: | -3.85 | Index: | N/A |
| Free Cash Flow: | -32828000.0 | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
President and CEO
Avg Cost/Share
$1.57
Shares
13,511
Total Value
$21,212.27
Owned After
1,178,162
SEC Form 4
CHIEF COMMERCIAL OFFICER
Avg Cost/Share
$1.54
Shares
8,023
Total Value
$12,355.42
Owned After
457,711
President and CEO
Avg Cost/Share
$1.54
Shares
42,638
Total Value
$65,662.52
Owned After
1,178,162
GENERAL COUNSEL
Avg Cost/Share
$1.54
Shares
14,594
Total Value
$22,474.76
Owned After
376,161
Chief Science &Techn. Officer
Avg Cost/Share
$1.54
Shares
14,497
Total Value
$22,325.38
Owned After
343,045
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| French Glendon E. III | LUNG | President and CEO | Jun 2, 2026 | Sell | $1.57 | 13,511 | $21,212.27 | 1,178,162 | |
| Rose Geoffrey Beran | LUNG | CHIEF COMMERCIAL OFFICER | Jun 1, 2026 | Sell | $1.54 | 8,023 | $12,355.42 | 457,711 | |
| French Glendon E. III | LUNG | President and CEO | Jun 1, 2026 | Sell | $1.54 | 42,638 | $65,662.52 | 1,178,162 | |
| Lehman David Aaron | LUNG | GENERAL COUNSEL | Jun 1, 2026 | Sell | $1.54 | 14,594 | $22,474.76 | 376,161 | |
| Radhakrishnan Srikanth | LUNG | Chief Science &Techn. Officer | Jun 1, 2026 | Sell | $1.54 | 14,497 | $22,325.38 | 343,045 |
SEC 8-K filings with transcript text
Apr 29, 2026 · 100% conf.
1D
+10.30%
$1.32
5D
+17.62%
$1.41
20D
+6.49%
$1.28
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.c706d217.1784665349.25decc62
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
Mar 4, 2026 · 100% conf.
1D
+10.08%
$1.58
Act: +11.81%
5D
+16.61%
$1.67
Act: +24.65%
20D
+9.00%
$1.56
lung-202603040001127537FALSE00011275372026-03-042026-03-04
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 4, 2026
(Exact name of Registrant as Specified in Its Charter)
Delaware001-3956277-0424412 (State or Other Jurisdiction(Commission File Number)(IRS Employer of Incorporation)Identification No.) 700 Chesapeake Drive Redwood City,CA94063 (Address of Principal Executive Offices)(Zip Code)
(650)364-0400 Registrant's telephone number, including area code
Not Applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.001 par valueLUNGThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On March 4, 2026, Pulmonx Corporation (the “Company”) issued a press release announcing its financial results for the fourth fiscal quarter and year ended December 31, 2025. A copy of the Company’s press release dated March 4, 2026, titled “Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results” is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The foregoing information (including the exhibit hereto) is being furnished under “Item 2.02 Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
Exhibit No.Description 99.1Press release dated March 4, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Pulmonx Corporation
Dated: March 4, 2026
By:/s/ Derrick Sung
Derrick Sung, Ph. D. Chief Operating Officer and Chief Financial Officer
Nov 12, 2025 · 100% conf.
1D
-22.59%
$1.52
Act: -18.37%
5D
-28.68%
$1.40
Act: -29.59%
20D
-26.91%
$1.43
Act: +28.06%
lung-202511120001127537FALSE00011275372025-11-122025-11-12
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 12, 2025
(Exact name of Registrant as Specified in Its Charter)
Delaware001-3956277-0424412 (State or Other Jurisdiction(Commission File Number)(IRS Employer of Incorporation)Identification No.) 700 Chesapeake Drive Redwood City,CA94063 (Address of Principal Executive Offices)(Zip Code)
(650)364-0400 Registrant's telephone number, including area code
Not Applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.001 par valueLUNGThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 12, 2025, Pulmonx Corporation (the “Company”) issued a press release announcing its financial results for the third fiscal quarter ended September 30, 2025. A copy of the Company’s press release dated November 12, 2025, titled “Pulmonx Reports Third Quarter 2025 Financial Results” is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The foregoing information (including the exhibit hereto) is being furnished under “Item 2.02 Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
Exhibit No.Description 99.1Press release dated November 12, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Pulmonx Corporation
Dated: November 12, 2025
By:/s/ Derrick Sung
Derrick Sung Chief Financial Officer
See how LUNG stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "LUNG Pulmonx Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.